Shoskes 2005.

Methods	Study design: Parallel RCT Time frame: September 2002 to August 2004
Participants	Inclusion criteria Setting: single centre Country: USA Cadaveric kidney transplant recipients Number: high‐dose group (14); low‐dose group (14); control group (15) Median age; range: high‐dose group (46; 33‐71); low‐dose group (52.5; 20‐74); control group (44; 19‐74) Sex (% male): high‐dose group (50); low‐dose group (50); control group (71) Exclusion criteria: NS
Interventions	High‐dose group one Oxy‐Q (480 mg of curcumin and 20 mg of quercetin) capsule twice a day Low‐dose group one Oxy‐Q capsule in the morning and one placebo capsule in the evening Control group Placebo (one capsule twice a day) Immunosuppression: daclizumab, tacolimus, mycophenolate mofetil, and steroids
Outcomes	SCr
Notes	Follow‐up: 30 days
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation method not described
Allocation concealment (selection bias)	Unclear risk	No information provided regarding the concealment of allocation
Blinding (performance bias and detection bias) All outcomes	Low risk	"Patients were randomized in a blinded fashion to receive either the Oxy‐Q or placebo". No additional information provided
Incomplete outcome data (attrition bias) All outcomes	Low risk	Withdrawals reported, intention‐to‐treat and per‐protocol analyses reported
Selective reporting (reporting bias)	Unclear risk	Study protocol is not separately available, however, the published report includes all expected outcomes
Other bias	High risk	Control group had a higher proportion of men (71%) compared with the 2 intervention groups (50%). Funding: not stated. Bioflavonoid preparation Oxy‐Q (Farr Labs, Santa Monica, CA)